



PTO/SB/08 Equivalent

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

| | | |
|---|----------------------|------------------------|
| (Multiple sheets used when necessary) SHEET 1 OF 1 | Application No. | 10/777053 |
| | Filing Date | February 10, 2004 |
| | First Named Inventor | John J.L. Simard |
| | Art Unit | 1644 |
| | Examiner | Francois P. Vandervegt |
| | Attorney Docket No. | MANNK.022C1 |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Document Number Number - Kind Code (if known) Example: 1,234,567 B1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|-------------------|----------|---|--------------------------------|-------------------------------|--|
| | 1 | | | | |
| | 2 | | | | |
| | 3 | | | | |
| | 4 | | | | |
| | 5 | | | | |
| | 6 | | | | |
| | 7 | | | | |
| | 8 | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ¹ |
|-------------------|----------|--|--------------------------------|----------------------------------|--|----------------|
| PV | 9 | WO 01/82963 A | 11/08/2001 | Simard et al. | | |
| | 10 | | | | | |
| | 11 | | | | | |
| | 12 | | | | | |
| | 13 | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
|-------------------|----------|---|----------------|
| | 14 | | |
| | 15 | | |
| | 16 | | |
| | 17 | | |
| | 18 | | |

2347614 / 020206

| | |
|---|----------------------------|
| Examiner Signature /F. Pierre Vandervegt/ | Date Considered 05/31/2006 |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

T¹ - Place a check mark in this area when an English language Translation is attached.



PTO/SB/08 Equivalent

**SUPPLEMENTAL INFORMATION
DISCLOSURE****STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 2

| | |
|----------------------|-------------------------|
| Application No. | 10/777,053 |
| Filing Date | February 10, 2004 |
| First Named Inventor | John Simard |
| Art Unit | 1644 |
| Examiner | Vandervegt, Francois P. |
| Attorney Docket No. | MANNK.022C1 |

U.S. PATENT DOCUMENTS

| Examiner Initials | Cite No. | Document Number Number - Kind Code (if known) Example: 1,234,567 B1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
|-------------------|----------|---|--------------------------------|-------------------------------|--|
| PV | 1. | 2003/0220239 | 11-2003 | Simard, et al. | |
| PV | 2. | 2005/0130920 | 06-2005 | Simard, et al. | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1 | Publication Date MM-DD-YYYY | Name of Patentee or Applicant | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ¹ |
|-------------------|----------|--|--------------------------------|-------------------------------|--|----------------|
| PV | 3. | WO 99/45954 | 09-1999 | Sette, et al. | | |
| PV | 4. | WO 01/55393 | 08-2001 | Wang, et al. | | |
| | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
|-------------------|----------|---|----------------|
| PV | 5. | Bergmann, et al. "Differential Effects of Flanking Residues on Presentation of Epitopes from Chimeric Peptides." J. Virol. 5306-5310 (1994). | |
| PV | 6 | Cellis, et al. "Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles." Mol. Immunol. 31(18): 1423-1430 (1994). | |
| PV | 7. | Chaux, et al. "Estimation of the Frequencies of Anti-Mage-3 Cytolytic T-Lymphocyte Precursors in blood from Individuals without Cancer." Int. J. Cancer. 77:538-542 (1998). | |
| PV | 8. | Eisenlohr, et al. "Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes." J. Exp. Med. 175: 481-487 (1992). | |
| PV | 9. | Gileadi, et al. "Effect of Epitope Flanking Residues on the Presentation of N-Terminal Cytotoxic T Lymphocyte Epitopes." Eur. J. Immunol. 29: 2213-2222 (1999). | |
| PV | 10. | Gnjatic, et al. "Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses." PNAS USA. 100(15): 8862-8867 (2003). | |
| PV | 11. | Gnjatic, et al. "Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs." J. Immunol. 170: 1191-1196 (2003). | |
| PV | 12. | Ochoa-Garay, et al. "The Ability of Peptides to Induce Cytotoxic T Cells <i>In Vitro</i> Does Not Strongly Correlate with their Affinity for the H-2Id Molecule: Implications for Vaccine Design and Immunotherapy." Molecular Immunology. 34(3): 273-281 (1997). | |
| PV | 13. | Perkins, et al. "Immunodominance: Intramolecular Competition Between T Cell Epitopes." J. Immunol. 146: 2137-2144 (1991). | |
| PV | 14. | Shastri, et al. "Presentation of Endogenous Peptide/MHC Class I Complexes is Profoundly Influenced by Specific C-Terminal Flanking Residues." J. Immunol. 155: 4339-4346 (1995). | |

| | | | |
|---|------------------------|-----------------|------------|
| Examiner Signature | /F. Pierre Vandervegt/ | Date Considered | 05/31/2006 |
| *Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

T¹ - Place a check mark in this area when an English language Translation is attached.

| | | |
|---|----------------------|-------------------------|
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Multiple sheets used when necessary)</i> | Application No. | 10/777,053 |
| | Filing Date | February 10, 2004 |
| | First Named Inventor | John Simard |
| | Art Unit | 1644 |
| | Examiner | Vandervegt, Francois P. |
| SHEET 2 OF 2 | Attorney Docket No. | MANNK.022C1 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-------------|---|----------------|
| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ¹ |
| PV | 15. | Wang, et al., "New NY-ESO Cancer Peptide or MHC Class II Restricted T Cell Epitopes, Useful as Immunogen and Vaccine for Inhibiting Cancer in a Mammal or as Protection From Metastasis." N Geneseq Accession No. AAD14184, 06 November 2001, page 2. | |
| PV | 16. | Theobald, et al. "The Sequence Alteration Associated with a Mutational Hotspot in P53 Protects Cells from Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope." J. Exp. Med. 188(6): 1017-1028 (1998). | |
| PV | 17. | Wang, et al. "Silencing of Immunodominant Epitopes by Contiguous Sequences in Complex Synthetic Peptides." Cell. Immunol. 143: 284-297 (1992). | |
| | | | |
| | | | |

2424141 SMA030706

| | | | |
|--|------------------------|-----------------|------------|
| Examiner Signature | /F. Pierre Vandervegt/ | Date Considered | 05/31/2006 |
| <p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p> | | | |

T¹ - Place a check mark in this area when an English language Translation is attached.